Announcement • May 22
CONMED Corporation Announces Board and Board Committee Appointments, Effective July 1, 2026 CONMED Corporation announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors, effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total of nine directors. Over three decades at Johnson & Johnson, both in the U.S. and internationally, Ms. Martin played a vital role in advancing the ambition of J&J MedTech, developing new categories and advancing standard of care for atrial fibrillation, stroke, and minimally invasive surgery. Most recently, she served as Company Group Chairman leading the Cardiovascular & Specialty Solutions Group from 2022 to 2025. As a member of the J&J MedTech leadership team, she ran a diverse portfolio of high growth businesses including Electrophysiology, Neurovascular Intervention, Ear Nose and Throat, and Breast Aesthetics. Before that, Ms. Martin led the Ethicon Endo Surgery business where she was instrumental in establishing the Robotic and Digital Surgery portfolio foundations. Ms. Martin holds an MBA from Wake Forest University and a graduate degree in marketing from Normandy Business School. Ms. Martin also serves on the Board of Directors at H.B. Fuller. Mr. Mirviss brings more than 35 years of healthcare industry leadership experience. Most recently, he served as Executive Vice President and Global President of Peripheral Interventions at Boston Scientific from 2020 to 2025, where he led a multi-billion dollar global business focused on therapies for vascular disease and cancer. In this role, he also had leadership responsibility for the Company’s Latin America and Canada regions, as well as its Government Affairs function. Previously, Mr. Mirviss served as Senior Vice President and Global President of Peripheral Interventions from 2013 to 2020, and as Global President of Peripheral Interventions from 2011 to 2013. Prior to these roles, Mr. Mirviss held positions of increasing responsibility at Boston Scientific, including Group Vice President of Global Marketing for the Company’s Cardiology, Rhythm and Vascular businesses. Mr. Mirviss holds a B.I.S. in Marketing from the University of Minnesota and an MBA from the University of St. Thomas. Announcement • May 02
CONMED Corporation Updates Earnings Guidance for the Fiscal Year 2026 CONMED Corporation updated earnings guidance for the fiscal year 2026. Based on the Company’s first quarter performance, management is raising its outlook for full-year 2026. Full-year 2026 reported revenue is now expected to be in the range of $1.350 billion to $1.375 billion, compared to prior guidance of $1.345 billion to $1.375 billion. The updated revenue outlook reflects an estimated 40 to 50 basis points of favorable foreign exchange impact, compared to the prior assumption of 0 to 50 basis points of favorable impact. This updated guidance also reflects an estimated $14.5 million to $17.5 million in revenue from gastroenterology products, reduced from the prior guidance of $21.0 million to $25.0 million due to the divestiture of the remaining gastroenterology portfolio. Announcement • Apr 08
CONMED Corporation, Annual General Meeting, May 18, 2026 CONMED Corporation, Annual General Meeting, May 18, 2026. Announcement • Apr 03
CONMED Corporation to Report Q1, 2026 Results on Apr 29, 2026 CONMED Corporation announced that they will report Q1, 2026 results After-Market on Apr 29, 2026 Announcement • Mar 16
CONMED Corporation Announces Appointment of Andrew Moller as Interim Principal Financial Officer, Effective March 15, 2026 CONMED Corporation announced that Andrew Moller, age 51, will be appointed Interim Principal Financial Officer of the Company effective March 15, 2026. Mr. Moller joined the Company in January 2025 as Vice President, Corporate Controller and was appointed as the Company's Principal Accounting Officer in April 2025. Prior to joining the Company, he was employed by Smith & Nephew from May 2019 to December 2024, where he most recently served as Global Controller and CFO Asia-Pacific. Prior to those roles, Mr. Moller served in a variety of roles at Stanley Black & Decker from 2011 to 2019, including Director of Internal Audit. Mr. Moller is a certified public accountant, and he holds a Master of International Business Studies from the University of South Carolina and a Bachelor of Science degree in Business Administration from the College of Charleston. Reported Earnings • Jan 30
Full year 2025 earnings released: EPS: US$1.52 (vs US$4.29 in FY 2024) Full year 2025 results: EPS: US$1.52 (down from US$4.29 in FY 2024). Revenue: US$1.37b (up 5.2% from FY 2024). Net income: US$47.1m (down 65% from FY 2024). Profit margin: 3.4% (down from 10% in FY 2024). Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Global Medical Equipment industry. Announcement • Jan 29
CONMED Corporation Provides Earnings Guidance for the Full Year of 2026 CONMED Corporation provided earnings guidance for the full year of 2026. The company expects full-year 2026 reported revenue between $1.345 billion and $1.375 billion. This represents year over year organic constant currency growth of approximately 4.5% to 6% over 2025 revenue when excluding sales of gastroenterology products from both years, and approximately 0 to 50 basis points of currency tailwind. Announcement • Jan 06
CONMED Corporation to Report Q4, 2025 Results on Jan 28, 2026 CONMED Corporation announced that they will report Q4, 2025 results After-Market on Jan 28, 2026 Announcement • Dec 08
Conmed Corporation Announces Its Intention to Exit Its Gastroenterology Product Lines CONMED Corporation announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization strategy. This exit allows CONMED to fully align operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair. Announcement • Sep 11
Conmed Corporation Adds Kim Kelderman to Its Board of Directors, Effective September 8, 2025 CONMED Corporation announced that Kim Kelderman will be joining its Board of Directors effective September 8, 2025. Mr. Kelderman has been President, Chief Executive Officer, and member of the Board of Bio-Techne since February 2024, having joined Bio-Techne in April 2018, as President, Diagnostics and Genomics, and having served as Chief Operating Officer from November 2023 to January 2024. Prior to Bio-Techne, Mr. Kelderman was employed at Thermo Fisher Scientific where he led three different businesses of increasing scale and complexity. Mr. Kelderman managed the Platforms and Content of the Genetic Sciences Division, where he was responsible for the Instrumentation, Software, Consumables and Assays businesses, and brands such as Applied Biosystems and legacy Affymetrix. Before joining Thermo Fisher, Mr. Kelderman served as Senior Segment Leader at Becton Dickinson, managing the global Blood Tubes "Vacutainer" business. Mr. Kelderman holds a Bachelor of Science degree from Hogeschool Heerlen of Applied Sciences in the Netherlands. Announcement • Aug 08
CONMED Corporation Declares Quarterly Cash Dividend, Payable on October 3, 2025 CONMED Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October 3, 2025, to all shareholders of record as of September 15, 2025. Announcement • Jul 31
Conmed Corporation Revises Earnings Guidance for Full Year 2025 Conmed Corporation revised earnings guidance for full year 2025. For the period, the company now expects revenue to be between $1.356 billion and $1.378 billion, compared to the prior guidance range of between $1.350 billion and $1.378 billion. Announcement • Jul 08
CONMED Corporation Announces Resignation of Independent Director Martha Aronson from the Board of Directors, Effective as of July 7, 2025 On July 7, 2025, CONMED Corporation announced that independent director Martha Aronson resigned from the Company's Board of Directors effective as of July 7, 2025. Announcement • Jul 03
CONMED Corporation to Report Q2, 2025 Results on Jul 30, 2025 CONMED Corporation announced that they will report Q2, 2025 results After-Market on Jul 30, 2025 Announcement • May 21
CONMED Corporation Announces Quarterly Cash Dividend, Payable on July 3, 2025 CONMED Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. Announcement • Apr 09
CONMED Corporation, Annual General Meeting, May 20, 2025 CONMED Corporation, Annual General Meeting, May 20, 2025. Location: conmed headquarters, 11311 concept blvd, fl 33773, largo United States Announcement • Apr 03
CONMED Corporation to Report Q1, 2025 Results on Apr 30, 2025 CONMED Corporation announced that they will report Q1, 2025 results After-Market on Apr 30, 2025 Announcement • Feb 06
CONMED Corporation Provides Financial Guidance for the First Quarter and Full Year of 2025 CONMED Corporation provided financial guidance for the first quarter and full year of 2025. The company expects full-year 2025 reported revenue between $1.344 billion and $1.372 billion. This represents year over year constant currency growth of approximately 4% to 6% and approximately 100 basis points to 120 basis points of currency headwind.
Currency is also a little stronger headwind in first quarter than it is for the full year, so the company expects reported sales in first quarter to be between $310 million and $316 million. Announcement • Jan 07
CONMED Corporation to Report Q4, 2024 Results on Feb 05, 2025 CONMED Corporation announced that they will report Q4, 2024 results on Feb 05, 2025 Announcement • Dec 10
CONMED Corporation Declares Quarterly Cash Dividend, Payable on January 3, 2025 CONMED Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on December 9, 2024, payable on January 3, 2025, to all shareholders of record as of December 20, 2024. Announcement • Nov 02
CONMED Corporation Revises Earnings Guidance for the Full Year 2024 CONMED Corporation revised earnings guidance for the full year 2024. Full year reported revenue is now expected to be between $1.300 billion and $1.305 billion, compared to the prior guidance range of $1.305 billion to $1.315 billion. Foreign currency is expected to have an immaterial impact on revenue for the full year. Announcement • Nov 01
CONMED Corporation Announces Chief Executive Officer Changes CONMED Corporation announced that Curt R. Hartman will retire as Chief Executive Officer (CEO) of the Company, effective January 1, 2025. Patrick Beyer, current Chief Operating Officer (COO) of CONMED, will succeed Mr. Hartman as CEO. Mr. Beyer joined CONMED in 2014 as President of International. In October 2020, Mr. Beyer was promoted to President of International and Global Orthopedics, where he took on the added responsibilities for the Company’s Global Orthopedics R&D and U.S. Orthopedics commercial business. In 2022, Mr. Beyer led the process of acquiring both In2Bones and BioRez. In April 2024, Mr. Beyer was promoted to the role of Chief Operating Officer (COO), in which he took on additional responsibility for leading the Company’s commercial businesses, as well as Operations, Distribution, Regulatory Affairs /Quality Assurance, and Customer Excellence. Prior to CONMED, Mr. Beyer spent 21 years at Stryker in leadership roles of increasing progression and nearly four years as CEO of ICNet International. He holds a B.A. in Economics from Kalamazoo College and an M.B. A from Western Michigan University. Mr. Beyer also completed the Advanced Management Program at Harvard University. Announcement • Oct 31
CONMED Corporation Announces Executive Changes CONMED Corporation announced that Curt R. Hartman will retire as President of the Company, effective January 1, 2025. Patrick Beyer, current Chief Operating Officer (COO) of CONMED, will succeed Mr. Hartman as President and CEO and will also be appointed as a member of the Company’s board, effective the same date. As part of the transition, Lead Independent Director Martha Goldberg Aronson will assume the position of Chair of the Board on October 31, 2024, while Mr. Hartman will continue serving as a Director through December 31, 2024. Mr. Hartman will remain with CONMED as an advisor through March of 2027. Mr. Beyer joined CONMED in 2014 as President of International. In October 2020, Mr. Beyer was promoted to President of International and Global Orthopedics, where he took on the added responsibilities for the Company’s Global Orthopedics R&D and U.S. Orthopedics commercial business. In 2022, Mr. Beyer led the process of acquiring both In2Bones and BioRez. In April 2024, Mr. Beyer was promoted to the role of Chief Operating Officer (COO), in which he took on additional responsibility for leading the Company’s commercial businesses, as well as Operations, Distribution, Regulatory Affairs /Quality Assurance, and Customer Excellence. Prior to CONMED, Mr. Beyer spent 21 years at Stryker in leadership roles of increasing progression and nearly four years as CEO of ICNet International. He holds a B.A. in Economics from Kalamazoo College and an M.B. A from Western Michigan University. Mr. Beyer also completed the Advanced Management Program at Harvard University. Announcement • Oct 04
CONMED Corporation to Report Q3, 2024 Results on Oct 30, 2024 CONMED Corporation announced that they will report Q3, 2024 results on Oct 30, 2024 Upcoming Dividend • Sep 09
Upcoming dividend of US$0.20 per share Eligible shareholders must have bought the stock before 16 September 2024. Payment date: 04 October 2024. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.1%. Lower than top quartile of Mexican dividend payers (7.3%). Lower than average of industry peers (1.6%). Board Change • Aug 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 6 highly experienced directors. Independent Director LaVerne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Aug 15
CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024 On August 14, 2024, CONMED Corporation announced that the employment of Stanley W. (Bill) Peters, the company’s President, Advanced Surgical & Advanced Endoscopic Technologies, will terminate on August 31, 2024. Reported Earnings • Aug 01
Second quarter 2024 earnings released: EPS: US$0.97 (vs US$0.45 in 2Q 2023) Second quarter 2024 results: EPS: US$0.97 (up from US$0.45 in 2Q 2023). Revenue: US$332.1m (up 4.5% from 2Q 2023). Net income: US$30.0m (up 118% from 2Q 2023). Profit margin: 9.0% (up from 4.3% in 2Q 2023). Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Global Medical Equipment industry. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Announcement • Aug 01
CONMED Corporation Revises Earnings Guidance for the Full Year 2024 CONMED Corporation revised earnings guidance for the full year 2024. For the year, the company expects reported revenue to be between $1.305 billion and $1.315 billion, compared to the prior guidance range of between $1.330 billion and $1.355 billion. Foreign currency is expected to have a negative impact on revenue in the range of $5 million to $10 million for the full year. Board Change • Jul 18
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 6 highly experienced directors. Independent Director LaVerne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 09
CONMED Corporation to Report Q2, 2024 Results on Jul 31, 2024 CONMED Corporation announced that they will report Q2, 2024 results After-Market on Jul 31, 2024 Upcoming Dividend • Jun 09
Upcoming dividend of US$0.20 per share Eligible shareholders must have bought the stock before 14 June 2024. Payment date: 05 July 2024. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Mexican dividend payers (6.6%). Lower than average of industry peers (1.6%). Declared Dividend • May 26
First quarter dividend of US$0.20 announced Shareholders will receive a dividend of US$0.20. Ex-date: 14th June 2024 Payment date: 5th July 2024 Dividend yield will be 0.8%, which is lower than the industry average of 3.1%. Payout Ratios Payout ratio: 30%. Cash payout ratio: 17%. Announcement • May 23
CONMED Corporation Declares Quarterly Cash Dividend, Payable on July 5, 2024 CONMED Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 22, 2024, payable on July 5, 2024, to all shareholders of record as of June 14, 2024. Recent Insider Transactions • May 03
Chief Operating Officer recently bought Mex$3.5m worth of stock On the 30th of April, Patrick Beyer bought around 3k shares on-market at roughly Mex$1,164 per share. This transaction amounted to 38% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months. Board Change • May 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. Independent Director LaVerne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Apr 10
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 7 highly experienced directors. Independent Director LaVerne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 09
CONMED Corporation, Annual General Meeting, May 22, 2024 CONMED Corporation, Annual General Meeting, May 22, 2024, at 13:30 Eastern Daylight. Location: CONMED Headquarters 11311 Concept Blvd Largo Florida United States Agenda: To elect eight directors to serve on the Company’s Board of Directors; to hold an advisory vote on named executive officer compensation; to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024; and to transact such other business as may properly be brought before the meeting or any adjournment or postponement thereof. Announcement • Apr 03
CONMED Corporation to Report Q1, 2024 Results on Apr 24, 2024 CONMED Corporation announced that they will report Q1, 2024 results After-Market on Apr 24, 2024 Announcement • Feb 28
CONMED Corporation Declares Quarterly Cash Dividend, Payable on April 5, 2024 CONMED Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on February 26, 2024, payable on April 5, 2024, to all shareholders of record as of March 15, 2024. Announcement • Feb 01
CONMED Corporation Provides Financial Guidance for the Full Year 2024 CONMED Corporation provided financial guidance for the full year 2024. The Company expects full-year 2024 reported revenue between $1.340 billion and $1.365 billion. This represents year-over-year growth of approximately 8% to 10%. Announcement • Dec 06
CONMED Corporation Announces Quarterly Cash Dividend, Payable on January 5, 2024 CONMED Corporation announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on December 4, 2023, payable on January 5, 2024, to all shareholders of record as of December 18, 2023. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 6 highly experienced directors. Independent Director LaVerne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 26
CONMED Corporation Updates Third Quarter Guidance for 2023 CONMED Corporation updated third quarter guidance for 2023. For the period, the Company now expects full-year revenue between $1.240 billion and $1.260 billion, compared to its prior guidance of between $1.230 billion and $1.260 billion. Board Change • Oct 11
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 6 highly experienced directors. Independent Director LaVerne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 05
CONMED Corporation to Report Q3, 2023 Results on Oct 25, 2023 CONMED Corporation announced that they will report Q3, 2023 results After-Market on Oct 25, 2023 Board Change • Sep 19
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 6 highly experienced directors. Independent Director LaVerne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Aug 11
CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2023 CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2023, to all shareholders of record as of September 15, 2023. Reported Earnings • Jul 28
Second quarter 2023 earnings released: EPS: US$0.45 (vs US$5.65 loss in 2Q 2022) Second quarter 2023 results: EPS: US$0.45 (up from US$5.65 loss in 2Q 2022). Revenue: US$317.7m (up 15% from 2Q 2022). Net income: US$13.7m (up US$182.0m from 2Q 2022). Profit margin: 4.3% (up from net loss in 2Q 2022). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Global Medical Equipment industry. Announcement • Jul 27
CONMED Corporation Revises Earnings Guidance for the Full Year 2023 CONMED Corporation revised earnings guidance for the full year 2023. Based on the second quarter results, the company is raising its revenue guidance for the full year 2023 and now expects revenue between $1.230 billion and $1.260 billion, compared to its prior guidance of between $1.205 billion and $1.250 billion. Board Change • Jul 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 6 highly experienced directors. Independent Director LaVerne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 06
CONMED Corporation to Report Q2, 2023 Results on Jul 26, 2023 CONMED Corporation announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Jul 26, 2023 Announcement • May 25
CONMED Corporation Announces Quarterly Cash Dividend, Payable on July 5, 2023 CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on July 5, 2023, to all shareholders of record as of June 15, 2023. Board Change • May 12
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. Independent Director LaVerne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Apr 13
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. Independent Director LaVerne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 05
Full year 2022 earnings released: US$2.68 loss per share (vs US$2.15 profit in FY 2021) Full year 2022 results: US$2.68 loss per share (down from US$2.15 profit in FY 2021). Revenue: US$1.05b (up 3.4% from FY 2021). Net loss: US$80.6m (down 229% from profit in FY 2021). Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Global Medical Equipment industry. Announcement • Feb 03
CONMED Corporation Provides Earnings Guidance for the Full Year 2023 CONMED Corporation provided earnings guidance for the full year 2023. The Company expects full-year 2023 reported revenue between $1.170 billion and $1.220 billion, which includes expected headwind from foreign exchange between 150 basis points and 200 basis points. Board Change • Jan 31
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 4 highly experienced directors. Independent Director Laverne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jan 10
CONMED Corporation to Report Q4, 2022 Results on Feb 02, 2023 CONMED Corporation announced that they will report Q4, 2022 results After-Market on Feb 02, 2023 Board Change • Dec 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. Independent Director Laverne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. Independent Director Laverne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buying Opportunity • Oct 29
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 24%. The fair value is estimated to be Mex$2,037, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: US$1.51 (vs US$0.51 in 3Q 2021) Third quarter 2022 results: EPS: US$1.51 (up from US$0.51 in 3Q 2021). Revenue: US$275.1m (up 11% from 3Q 2021). Net income: US$46.2m (up 209% from 3Q 2021). Profit margin: 17% (up from 6.0% in 3Q 2021). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Global Medical Equipment industry. Buying Opportunity • Oct 11
Now 21% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be Mex$1,937, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Meanwhile, the company became loss making. Board Change • Oct 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. Independent Director Laverne Council was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Sep 18
Chairman of the Board recently sold Mex$6.6m worth of stock On the 15th of September, Curt Hartman sold around 4k shares on-market at roughly Mex$1,884 per share. This transaction amounted to 3.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Curt has been a net seller over the last 12 months, reducing personal holdings by Mex$14m. Buying Opportunity • Sep 07
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 21%. The fair value is estimated to be Mex$2,186, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.3% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 12% in a year. Earnings is forecast to grow by 97% in the next year. Upcoming Dividend • Sep 07
Upcoming dividend of US$0.20 per share Eligible shareholders must have bought the stock before 14 September 2022. Payment date: 05 October 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Mexican dividend payers (6.5%). Lower than average of industry peers (1.8%). Reported Earnings • Jul 28
Second quarter 2022 earnings released: US$5.65 loss per share (vs US$0.46 profit in 2Q 2021) Second quarter 2022 results: US$5.65 loss per share (down from US$0.46 profit in 2Q 2021). Revenue: US$277.2m (up 8.6% from 2Q 2021). Net loss: US$168.3m (down US$181.6m from profit in 2Q 2021). Over the next year, revenue is forecast to grow 12%, compared to a 20% growth forecast for the industry in Mexico. Buying Opportunity • Jun 17
Now 20% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be Mex$2,279, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.7% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 12% in a year. Earnings is forecast to grow by 60% in the next year. Upcoming Dividend • Jun 07
Upcoming dividend of US$0.20 per share Eligible shareholders must have bought the stock before 14 June 2022. Payment date: 05 July 2022. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of Mexican dividend payers (5.9%). Lower than average of industry peers (1.6%).